Melphalan and Sorafenib drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Melphalan (melphalan) and Sorafenib (sorafenib). Common drug interactions include adenoviral hepatitis among females and acute graft versus host disease among males.

The phase IV clinical study analyzes what interactions people have when they take Melphalan and Sorafenib. It is created by eHealthMe based on reports of 30 people who take the same drugs from the FDA, and is updated regularly.

What is Melphalan?

Melphalan has active ingredients of melphalan. eHealthMe is studying from 20,052 Melphalan users. Check the latest studies of Melphalan.

What is Sorafenib?

Sorafenib has active ingredients of sorafenib. eHealthMe is studying from 3,201 Sorafenib users. Check the latest studies of Sorafenib.

On Jul, 04, 2026

30 people who take Melphalan and Sorafenib together, and have interactions are studied.

Melphalan and Sorafenib drug interactions.

What are the common drug interactions of Melphalan and Sorafenib, by gender? *:

female:

Adenoviral hepatitis (viral hepatitis)
Respiratory failure (inadequate gas exchange by the respiratory system)
Septic shock (shock due to blood infection)
Adenovirus infection
Pneumonia adenoviral (viral pneumonia caused by an adenovirus)
Leukopenia (less number of white blood cells in blood)
Tachycardia (a heart rate that exceeds the range of 100 beats/min)
Pyrexia (fever)
Hepatitis (inflammation of the liver)
Pneumonia

male:

Acute graft versus host disease (acute complication following an allogeneic tissue/blood transplant)
Alanine aminotransferase increased
Disseminated intravascular coagulation (systemic activation of blood coagulation)
Febrile neutropenia (fever with reduced white blood cells)
Hepatic failure (liver failure)
Stomatitis (inflammation of mucous membrane of mouth)
Aspartate aminotransferase increased
Cardiac failure acute
Palmar-plantar erythrodysaesthesia syndrome (hand-foot syndrome)
Pulmonary haemorrhage (acute bleeding from the lung)

What are the common drug interactions of Melphalan and Sorafenib, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

Acute graft versus host disease (acute complication following an allogeneic tissue/blood transplant)
Alanine aminotransferase increased
Aspartate aminotransferase increased
Cardiac failure acute
Palmar-plantar erythrodysaesthesia syndrome (hand-foot syndrome)
Pulmonary haemorrhage (acute bleeding from the lung)
Renal failure acute (rapid kidney dysfunction)
Respiratory failure (inadequate gas exchange by the respiratory system)
Acute myeloid leukaemia recurrent (acute cancer in which the bone marrow makes abnormal myeloblast- recurrent)
Bone marrow toxicity (decrease in cells responsible for providing immunity, carrying oxygen, and those responsible for normal blood clotting)

10-19:

Acute graft versus host disease (acute complication following an allogeneic tissue/blood transplant)
Chronic graft versus host disease (immune cells attack the host's body cells after transplant)
Cytomegalovirus infection
Febrile neutropenia (fever with reduced white blood cells)
Stomatitis (inflammation of mucous membrane of mouth)

20-29:

n/a

30-39:

n/a

40-49:

Adenoviral hepatitis (viral hepatitis)
Respiratory failure (inadequate gas exchange by the respiratory system)
Febrile neutropenia (fever with reduced white blood cells)
Atypical pneumonia (acute respiratory disease marked by high fever and coughing)
Coagulopathy (blood's ability to clot is impaired)
Lung consolidation (a condition whereby the lung tissues solidify because of the accumulation of solid and liquid material in the air spaces)
Septic shock (shock due to blood infection)
Adenovirus infection
Pneumonia adenoviral (viral pneumonia caused by an adenovirus)
Leukopenia (less number of white blood cells in blood)

50-59:

n/a

60+:

n/a

What are the existing conditions these people have? *

Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 18 people, 60.00%
Graft Versus Host Disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body): 9 people, 30.00%
Bone Marrow Conditioning Regimen: 5 people, 16.67%
Neoplasm Malignant (cancer tumour): 4 people, 13.33%
Acute Myeloid Leukaemia (In Remission): 2 people, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Melphalan and Sorafenib?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously